ClinicalTrials.gg
Sign In
CompletedNCT03345667Updated Nov 17, 2017

Assessment of Color Vision in Diabetic Patients

An observational study in Retinopathy, Diabetic, sponsored by Instituto de Olhos de Goiania. Completed at 1 site in Brazil. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by Instituto de Olhos de Goiania · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Retrospective
Enrollment
30
Ages
1 Year to 100 Years
Sex
All
01

Study summary

Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema

02

Conditions studied

  • Retinopathy, Diabetic

Browse trials for

03

In context

Diabetic Retinopathy

778 studies on the registry are indexed under Diabetic Retinopathy; 142 are open to participants now.

This study's enrollment of 30 is below the median of 172 across 263 observational studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Instituto de Olhos de Goiania is the lead sponsor of 27 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema. Using the Ishirara's test to evaluate the possible visual loss.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having diabetic retinopathy with macular edema

Exclusion criteria

Exclusion Criteria:

  • Not having diabetic retinopathy with macular edema
05

Study design

Observational model
Ecologic or community
Time perspective
Retrospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Anti-Vegf

    Use intravitreous anti-vegf

    Drug: lucentis

Interventions

  • Druglucentis

    Use of lucentis and other anti-vegf in patients with diabetic retinopathy

06

What researchers measure

Primary outcomes

  1. Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema

    Using the Ishihara's test to analise the possible loss of vision

    Time frame: 3 months

Secondary outcomes

  1. Frame between the injections

    Ant-Vegf

    Time frame: 1 months

07

Study locations

1 site
  • Instituto de Olhos de Goiania
    Goiânia, Goias 74110120, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Oct 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2017
First posted
Nov 17, 2017
StartActual
Aug 1, 2017
Primary completionActual
Oct 1, 2017
CompletionActual
Oct 30, 2017
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03345667
Lead sponsor
Instituto de Olhos de Goiania
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Aug 1, 2017
Primary completion
Oct 1, 2017
Completion
Oct 30, 2017
Last update
Nov 17, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetic Retinopathy →

Other studies from this sponsor

Instituto de Olhos de Goiania

Start the discussion